TS-172
Phase 3Small molecule
TS-172 is one of 25 small molecule programs targeting Hyperphosphatemia. It is currently in Phase 3.
2
Indications
12
Total Trials
3
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Hepatic Impairment
#DrugCompanyPhaseTrials
1Fotivda
RochePhase 1
Vanflyta
Daiichi SankyoPhase 1
TS-172
TTaisho Pharmaceutical Co., Ltd.
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 1
DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 1
AZD6234
AstraZenecaPhase 1
Lipaglyn
ZZydus Therapeutics Inc.
Phase 1
Atirmociclib
PfizerPhase 1
AZD9550
AstraZenecaPhase 1
Casdatifan
Arcus BiosciencesPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperphosphatemia5 trials
Adult Subject3 trials
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS-172. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTaisho Pharmaceutical Co., Ltd.